Prognostic Value of PLR On Cardiovascular Complications in Chronic Hemodialysis Patients

April 8, 2026 updated by: Hanaa Mohammad Aly, Minia University

Prognostic Value of the Platelet to Lymphocyte Ratio on Cardiovascular Complications in Chronic Hemodialysis Patients

Prognostic value of platelet to lymphocyte ratio on cardiovascular complications in chronic hemodialysis patients this study was done to determine the prognostic value of PLR on cardiovascular complications like vascular calcifications and atherosclerosis in carotid and coronary arteries in chronic hemodialysis patients

Study Overview

Status

Completed

Conditions

Detailed Description

Prognostic value of platelet to lymphocyte ratio on cardiovascular complications in chronic hemodialysis patients this study was done to determine the prognostic value of PLR on cardiovascular complications like vascular calcifications and atherosclerosis in carotid and coronary arteries as these complications are common and well-known causes of morbidity and mortality in chronic hemodialysis patients

Study Type

Observational

Enrollment (Actual)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
    • Elminya
      • Minya, Elminya, Egypt, 2422998
        • Kiriazy

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

patients undergoing hemodialysis for more than 3 months

Description

Inclusion Criteria:

  • patients undergoing hemodialysis for more than 3 months who agreed to be included in the study

Exclusion Criteria:

  • We are going to exclude patients who have:

    • Younger than 18 year- old or Older than 75 year-old,
    • Patients with positive serum marker of anti-hepatitis C virus (anti-HCV), hepatitis B surface antigen (HBsAg) and human immunodeficiency virus (HIV).
    • Alcohol or illicit drug abusers.
    • Inflammatory state due to infection,

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
disease group
60 patients of ESKD on maintenance hemodialysis were investigated for platelet to lymphocyte ratio, S.PTH , S.Ca , S.Phosp Echocardiography and carotid duplex
Healthy control group
20 healthy persons were investigated for platelet to lymphocyte ratio to be compared with the disease group results

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To evaluate the association between platelet-to-lymphocyte ratio and cardiovascular complications in patients on chronic maintenance hemodialysis.
Time Frame: 6 months

Primary Outcome Association between PLR and cardiovascular complications in chronic hemodialysis patients.

Secondary Outcomes optimal PLR cutoff for cardiovascular complication prediction relation of PLR to individual cardiovascular diagnoses relation of PLR to cardiovascular hospitalization relation of PLR to cardiovascular mortality
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Minia University

Investigators

  • Study Chair: Hassan Mohammad Mohyedin, Professor of internal medicine, faculty of medicine elminya university

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 4, 2024

Primary Completion (Actual)

June 4, 2024

Study Completion (Actual)

August 4, 2024

Study Registration Dates

First Submitted

April 3, 2026

First Submitted That Met QC Criteria

April 3, 2026

First Posted (Actual)

April 9, 2026

Study Record Updates

Last Update Posted (Actual)

April 13, 2026

Last Update Submitted That Met QC Criteria

April 8, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • PLR

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

privacy

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Complications in Hemodialysis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe